During the corresponding time, Genedx Holdings Corp recorded a revenue increase by 18.2 % year on year, sequentially revenue fell by -16.4 %. While revenue at the Genedx Holdings Corp 's corporate clients
Genedx Holdings's Comment on Sales, Marketing and Customers
The company serves customers including third-party payors, patients, business-to-business clients, and other healthcare partners. Its revenue is primarily derived from diagnostic test reports, with plans to expand into data and information solutions, newborn screening products, and interpretation services. Approximately 1.5% of revenue comes from referral sources outside the United States, with expectations to increase international revenue. The company collaborates on studies with Seattle Children’s Hospital, University of Washington, New York-Presbyterian, Columbia University, New York State Department of Health, and Illumina, Inc. Its market segments include molecular genetic testing, consulting services, and genetic information services for health and wellness. Competitors include Baylor Genetics, Tempus (via Ambry Genetics), Variantyx, Rady Children’s Hospital, and other commercial and academic laboratories. The company experiences seasonal revenue fluctuations, with higher revenue in the fourth quarter and lower revenue in the first quarter due to insurance deductible cycles.
GeneDx Holdings Corp. Under Investigation for Potential Misleading Business Information: Shareholders Rights at Stake NEW YORK, August 29, 2025 - In what could be a significant development for investors in the biotechnology sector, Rosen Law Firm, a globally recognized investor rights law firm, is actively investigating potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS). This investigation stems from concerns over allegations that GeneDx Holdings Corp. might have disseminated materially misleading business information to the investing public.GeneDx Holdings Corp., a company at the forefront of genetic diagnostics, has recently exhibited troubling financial metrics...
Revolutionary Genomic Testing: Transforming Neonatal Intensive Care and Newborn Screening Recent advancements in genomic testing have the potential to redefine neonatal intensive care unit (NICU) protocols and standards for newborn health screening. GeneDx, a trailblazer in genomic research and diagnostics, has made significant contributions to this rapidly evolving field. Through their Seqfirst-neo study, presented in the American Journal of Human Genetics, GeneDx showcased the transformative impact of genomic testing in the NICU. Additionally, the company s research endeavors and upcoming presentations at the 2024 American Society of Human Genetics (ASHG) annual meeting underscore their pivotal role in adv...
Through this partnership, GeneDx will leverage Komodo Health s extensive data resources to gain deeper insights into rare diseases. With access to the world s largest rare disease dataset, GeneDx will be able to enhance diagnostic accuracy, develop targeted therapies, and improve patient outcomes. This collaboration marks a significant milestone for GeneDx as it continues to revolutionize the field of genomic sequencing.In addition to the partnership with Komodo Health, GeneDx will also participate in a panel presentation at the upcoming World Orphan Drug Congress. The panel discussion will focus on the pivotal role of genomic sequencing in advancing precision medicine. GeneDx s involvement in this prestigio...
Genedx Holdings’s Comment on Sales, Marketing and Customers
The company serves customers including third-party payors, patients, business-to-business clients, and other healthcare partners. Its revenue is primarily derived from diagnostic test reports, with plans to expand into data and information solutions, newborn screening products, and interpretation services. Approximately 1.5% of revenue comes from referral sources outside the United States, with expectations to increase international revenue. The company collaborates on studies with Seattle Children’s Hospital, University of Washington, New York-Presbyterian, Columbia University, New York State Department of Health, and Illumina, Inc. Its market segments include molecular genetic testing, consulting services, and genetic information services for health and wellness. Competitors include Baylor Genetics, Tempus (via Ambry Genetics), Variantyx, Rady Children’s Hospital, and other commercial and academic laboratories. The company experiences seasonal revenue fluctuations, with higher revenue in the fourth quarter and lower revenue in the first quarter due to insurance deductible cycles.
Sources:
Genedx Holdings Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Genedx Holdings Corp’s corporate clients.
For your research, we’ve provided 9 tables on Genedx Holdings Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
99.3 %